Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/149485
Full metadata record
DC FieldValueLanguage
dc.creatorOliveira, O
dc.creatorGaio, R
dc.creatorCorreia-Neves, M
dc.creatorRito, T
dc.creatorDuarte, R
dc.date.accessioned2023-05-23T14:23:20Z-
dc.date.available2023-05-23T14:23:20Z-
dc.date.issued2021
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/10216/149485-
dc.description.abstractTreatment of drug-resistant tuberculosis (TB), which is usually less successful than that of drug-susceptible TB, represents a challenge for TB control and elimination. We aimed to evaluate treatment outcomes and to identify the factors associated with death among patients with MDR and XDR-TB in Portugal. We assessed MDR-TB cases reported for the period 2000-2016, using the national TB Surveillance System. Treatment outcomes were defined according to WHO recommendations. We identified the factors associated with death using logistic regression. We evaluated treatment outcomes of 294 MDR- and 142 XDR-TB patients. The treatment success rate was 73.8% among MDR- and 62.7% among XDR-TB patients (p = 0.023). The case-fatality rate was 18.4% among MDR- and 23.9% among XDR-TB patients. HIV infection (OR 4.55; 95% CI 2.31-8.99; p < 0.001) and resistance to one or more second-line injectable drugs (OR 2.73; 95% CI 1.26-5.92; p = 0.011) were independently associated with death among MDR-TB patients. HIV infection, injectable drug use, past imprisonment, comorbidities, and alcohol abuse are conditions that were associated with death early on and during treatment. Early diagnosis of MDR-TB and further monitoring of these patients are necessary to improve treatment outcome.
dc.description.sponsorshipThis work was developed under the scope of the project NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023, supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) and projects PTDC/SAU-PUB/29521/2017. This work was partially supported by “Contratos-Programa” UIDB/50026/2020 and UIDB/04050/2020 funded by national funds through the FCT - Foundation for Science and Technology, I.P. OO is supported by the project NORTE-08-5369-FSE-000041, financed by the Operational Program NORTE 2020 and co-financed by the European Social Fund through a doctoral grant (UMINHO/BD/47/2016). This work was also supported by national funds through the FCT, I.P., under the project UIDB / 04750/2020.
dc.language.isoeng
dc.publisherPublic Library of Science
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/SAU-PUB/29521/2017/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/50026/2020/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04050/2020/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04750/2020/PT
dc.relation.ispartofPLoS One. 2021 Apr 20;16(4):e0250028
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleEvaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000-2016
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Saúde Pública da Universidade do Porto
dc.identifier.doi10.1371/journal.pone.0250028
dc.relation.publisherversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0250028#ack
Appears in Collections:ISPUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
oliveira-po-2021.pdf607.19 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons